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Introduction
Preeclampsia usually occurs after week 20 of gestation
and features hypertension and an increased peripheral
vascular resistance. The mechanisms are unknown (1).
Several lines of evidence implicate angiotensin II (Ang II)
and its binding site, the AT1 receptor. Preeclamptic
patients manifest exaggerated pressor responses to Ang
II. Gant et al. (2) infused Ang II into pregnant patients
from week 10 of pregnancy onward and observed that
those who later developed sustained hypertension
required diminishing amounts of Ang II to obtain a sim-
ilar pressor response. One possible explanation for this
phenomenon might be increased expression of the AT1
receptor. Baker et al. (3) also performed Ang II infusion
experiments in pregnant patients and identified five
patients who subsequently developed hypertension after
week 20. These women were compared with seven who
did not develop hypertension. The platelets of the
preeclamptic women exhibited increased calcium sig-
naling and increased binding sites for Ang II. The
authors suggested increased stimulus–effect coupling in
terms of Ang II responses in preeclamptic patients. We
also observed increased cytosolic calcium responses in
the platelets of preeclamptic patients in response to Ang
II (4). However, circulating levels of Ang II are not
increased in preeclampsia (5–7). In an earlier study of
patients with essential hypertension, we observed a
remarkably high incidence of circulating antibodies that
cross-reacted with the a 1-adrenoceptor and stimulated
its signaling mechanism (8). In the present study, we test-
ed the hypothesis that circulating antibodies to a vascu-
lar receptor might be responsible for the hypertension
observed in preeclampsia. We employed a bioassay of
beating neonatal rat cardiomyocytes, as well as Western
blotting and confocal microscopy. We found that
immunoglobulin from preeclamptic women contains a
factor that binds to, and stimulates, the AT1 receptor.
Methods
Cell culture. Isolation and cultivation of neonatal heart cells were
performed as described previously (9). Briefly, single cells were
dissociated from the minced ventricles of Wistar rats (1–2 days
old) with a 0.25% solution of crude trypsin and were cultured as
monolayers with a density of 800 cells/mm2 in Halle SM 20-I
medium equilibrated with humidified air. The medium 
contained 10% heat-inactivated FCS and 2 m mol/l fluoro-
deoxyuridine (Serva, Heidelberg, Germany) the latter to prevent
proliferation of nonmuscle cells. On the third or fourth days, the
cells were incubated for 2 h in 2 ml fresh serum-containing
medium. Seven to 10 selected cells or synchronously contracting
cell clusters per flask were counted for 15 s. This procedure was
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AT1 receptor antibody. The protein kinase C (PKC) inhibitor calphostin C prevented the stimulatory
effect. Our results suggest that preeclamptic patients develop stimulatory autoantibodies against the
second extracellular AT1 receptor loop. The effect appears to be PKC-mediated. These novel autoanti-
bodies may participate in the angiotensin II–induced vascular lesions in these patients.
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repeated twice in different cultures to yield results representing
a total of up to 30 cells for each sample. Immunoglobulin frac-
tions, agonist and antagonist drugs, peptides, etc. were added
singly or cumulatively as indicated. The basal contraction rate of
the spontaneously beating cardiomyocytes was 162 ± 4 min.
Preparation of the immunoglobulin fraction. The immunoglob-
ulin fraction was isolated from 1- to 2-ml serum samples by
ammonium sulfate precipitation at a saturation of 40%. The
precipitates were washed and dissolved in dialysis buffer (154
mmol/l NaCl, 10 mmol/l sodium phosphate; pH 7.2). The
procedure of precipitating, washing, and dissolving was
repeated twice. Finally, the immunoglobulins were taken up
in 2 ml PBS (pH 7.2) and dialyzed at 4°C for 30 hours against
1 l of dialysis buffer. The buffer was changed five times dur-
ing dialysis. Recently we also employed specific anti–human
IgG columns, as well as protein A columns, and obtained sim-
ilar results. For detection of autoantibodies, the immunoglob-
ulin fractions were added at a dilution of 1:20 to the flasks.
For the neutralization experiments, the synthetic peptide cor-
responding to the sequence of the second extracellular loop
of the human AT1 receptor position 165–191 (I-H-R-N-V-F-F-
I-I-N-T-N-I-T-V-C-A-F-H-Y-E-S-Q-N-S-T-L) was added in
excess (0.5 m g in 50 m l) to 50 m l of the immunoglobulin frac-
tion. The mixtures were shaken and placed in a refrigerator
for 1 h. The 100- m l samples were then added to neonatal rat
heart muscle cells cultured in 2 ml medium to a final dilution
of 1:40. The beating rate was counted for 15 s, 5 min, and 60
min after the addition of the peptide/immunoglobulin mix-
ture. Affinity purification was performed. The immunoglob-
ulin fractions from the patients were loaded on a Sepharose
4B CNBr-activated gel (Pharmacia Biotech AB Uppsala, Swe-
den) to which the peptide corresponding to the second extra-
cellular loop of the AT1 receptor was covalently linked. The
antibodies were eluted with 3 M potassium thiocyanate (pH
7.4) followed by immediate extensive dialysis against PBS.
Immunocytochemistry and Western blotting. Rat aortic vascular
smooth muscle cells (VSMCs) were obtained as described earli-
er (10). The cells were fixed with 4% paraformaldehyde and per-
meabilized with 80% methanol at –20°C. We used commercial-
ly available antibodies directed against the AT1 receptor (Santa
Cruz Biotechnology Inc., Santa Cruz, California, USA). Cells
were then exposed to the secondary antibody (Cy2- and Cy3-
conjugated anti–rabbit or anti–human IgG, at 1:100, 1%
BSA/PBS; Dianova, Hamburg, Germany) for 60 min. The
preparation was mounted with 50% glycerol under a glass cov-
erslip on a Nikon-Diaphot microscope (Nikon Tokyo, Japan).
A Bio-Rad MRC 600 confocal imaging system (Bio-Rad Labo-
ratories, Munich, Germany) with an argon/krypton laser was
used. At least 10–18 cells from each of at least four experiments
were examined under each experimental condition. The results
were reproduced by two separate investigators and multiple
experiments were done. The observers were unaware of the
experimental design and antibodies used.
Western blot analysis was carried out as described previously
(10). After the experiments, the VSMCs were exposed to either
affinity-purified IgG fractions or antibodies directed against the
AT1 receptor (see above) diluted in incubation buffer. A final
incubation was carried out in Tris-buffered saline (TBS) with
peroxidase-conjugated anti–rabbit or anti–human IgG (Pierce
Chemicals, Oud-Beijerland, the Netherlands). The results were
viewed by chemiluminescence (Renaissance; Du Pont NEN
Research Products, Boston, Massachusetts, USA) 
Patients. Forty-eight pregnant women were recruited from
the Departments of Obstetrics and Gynecology of the Univer-
sity of Erlangen-Nürnberg, the University Hospital Virchow
Klinikum-Charité, and city hospitals in Buch and Neukölln
(Berlin, Germany). Twenty-five women had preeclampsia
defined by hypertension and proteinuria after week 20 of preg-
nancy; 19 were delivering for the first time, while 6 were mul-
tiparous (1). One of these women had essential hypertension
and developed superimposed preeclampsia manifested as pro-
teinuria and worsened hypertension after week 20 of preg-
nancy. Hypertension was defined as a blood pressure of
‡ 140/90 mmHg after week 20 of pregnancy. Proteinuria was
defined as “a positive reading” from a random urine sample or
‡ 300 mg in a 24-h urine collection. The preeclampsia group
ranged in age from 21–37 years (mean age: 29 years). The 12
nonpreeclamptic healthy pregnant patients ranged in age from
21–32 years (mean age: 27 years). Ten age-matched pregnant
women with preexisting essential hypertension, aged 20–40
years (mean age: 32 years), were also studied. All women gave
written, informed consent as determined by our committee on
human subjects. For serum preparation, the samples were cen-
trifuged at 4,000 g for 30 min and stored at –20°C.
Reagents. Prazosin was purchased from Sigma-Aldrich
Chemie (Deisenhofen, Germany), and losartan was obtained
from Merck Sharp & Dohme (Munich, Germany). All other
chemicals were of analytical grade. PD 123319 was donated by
Parke-Davis Co. (Ann Arbor, Michigan, USA)
Statistics. Results are expressed as the means ± SEM. Student’s
t test was used to compare variables between the groups. Values
of P < 0.05 are significant.
Results
Figure 1 shows the increase in beats per minute (bpm) of
spontaneously beating neonatal rat cardiomyocytes
when exposed to immunoglobulin from 25 patients with
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Figure 1
Increase in beat number of spontaneously beating
neonatal rat cardiomyocytes when exposed to
immunoglobulin from 25 patients with preeclampsia,
7 patients after delivery, and 12 patients with normal
pregnancy. Nulliparous patients are shown with filled
circles, while multiparous patients are designated with
an x. Ten pregnant patients with essential hypertension
were studied; five (open circles) had immunoglobulins
that increased the beating rate. This increase was abol-
ished by prazosin, implying involvement of the a 1-
adrenoceptor in these five patients. **Different from
preceding group (P < 0.01).
preeclampsia, 7 patients after delivery, 12 patients with
normal pregnancies, and hypertensive patients who
became pregnant. Preeclamptic immunoglobulin
increased the beat number by 23 bpm, which was differ-
ent from immunoglobulin from women with normal
pregnancies (P < 0.01) and similar to the effect of 0.1 m M
Ang II (see below). Seven preeclamptic women were stud-
ied after delivery. Their serum affected the spontaneous
beating rate; however, the rate had decreased by 50% but
remained above control levels (P < 0.01). The postpartum
samples were obtained on days 5, 6, 7, 9, and 29 after
delivery. We do not have sufficient data for later time
points, particularly between days 9 and 29, to calculate
an accurate half-life. The immunoglobulin samples from
5 of 10 hypertensive pregnant, but nonpreeclamptic,
patients appeared to contain a fraction that interacted
with the a 1-adrenoceptor, as we described earlier (8).
These five women had immunoglobulin that increased
the beats per minute by 10; however, the addition of pra-
zosin abolished this increase.
We next studied the effect of Ang II directly on the
spontaneous beating rate and observed a dose–response
relationship as shown in Figure 2a. At concentrations
between 0.001 and 0.1 m M, a dose-dependent increase in
the spontaneous beating rate was observed, which lev-
eled off at higher concentrations. This effect was selec-
tively blocked by losartan but not by the AT2 receptor
blocker PD 123319 (not shown). A dose–response curve
from the immunoglobulin fraction from two preeclamp-
tic patients is shown in Figure 2b. A linear response from
dilutions of 1:400 to 1:40 was observed. The response
was maximal at a dilution of 1:40, and increasing the
concentration further did not increase the response.
Again, 10 separate measurements were performed at
each dilution from both patients. Figure 3 shows the
effects of angiotensin receptor blockade with PD 123319
directed against the AT2 receptor and losartan directed
against the AT1 receptor, as well as the combination of
losartan and prazosin, on the increase in beat number
induced by immunoglobulin from preeclamptic
patients. Immunoglobulin samples from 10 preeclamp-
tic patients were studied. Immunoglobulin from all
preeclamptic patients increased the beats per minute by
20–27. PD 123319 had no effect, indicating that the AT2
receptor was not involved in the responses. Losartan
abolished the increase in beats per minute completely in
five of the samples tested and reduced the beats per
minute by two-thirds in five of the remaining samples.
In these samples, the increase was abolished by prazosin.
These responses raised the possibility that immunoglob-
ulin from preeclamptic patients contains a fraction that
increases the spontaneous cardiomyocyte beat frequen-
cy through an interaction with the AT1, but not the AT2,
receptor. Furthermore, in half of the patients, an addi-
tional a 1-adrenergic response was identified.
We next tested the specificity of the response by prein-
cubating the immunoglobulin from the preeclamptic
patients with a peptide consisting of the second extra-
cellular loop of the AT1 receptor, as shown in Figure 4.
This maneuver decreased the stimulatory effect on car-
diomyocyte beat frequency from 25 to 8 bpm. Adding
prazosin abolished the residual stimulatory effect. To
rule out a nonspecific peptide effect, we preincubated
the patients’ immunoglobulin with a peptide consisting
of the second extracellular loop of the b 1-adrenergic
receptor. This peptide had no effect on the spontaneous
beating rate. The responses indicate inhibition of anti-
body directed against the AT1 receptor by the peptide,
thereby verifying the specificity of the response. A resid-
ual response mediated by the a 1-adrenergic receptor was
abolished by the addition of prazosin.
We then tested immunoglobulins from five patients who
were preexposed to peptides containing the amino acid
sequence of the first, second, and third extracellular AT1
receptor loops (data not shown). Only peptides from the
second extracellular loop blocked the effect. We next added
anti–human IgG and anti–human IgM antibody to the
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Figure 2
(a) Dose–response relationship between Ang II concentrations and sponta-
neous beating rate. A plateau was observed after 0.1 m M. (b) Dose–response
relationship of immunoglobulin fractions from two preeclamptic women
(each measured 10 times) on the spontaneous beating rate. Dilutions from
1:20 to 1:400 were prepared. A linear response from 1:400 to 1:40 was
observed, after which a maximum effect was observed. Ang II, angiotensin II.
immunoglobulin fraction from seven preeclamptic
patients. The anti–human IgG antibody abolished the
effect, whereas the anti–human IgM antibody had no effect
(data not shown). These results support the notion that an
IgG antibody in the immunoglobulin fraction from
preeclamptic women was responsible for the effect. We
used the affinity column–purified material to reexamine
possible epitopes on the second loop of the AT1 receptor.
Figure 5 shows the effects of short, overlapping peptides
corresponding to the second extracellular loop of the AT1
receptor. Only the amino acid sequence AFHYESQ abol-
ished the increase in the spontaneous beating rate in all
nine patients tested. These findings suggest that this site
contains the binding epitopes of the antibody.
In Figure 6, we show Western blot bands produced by
commercially available AT1 receptor antibody (Figure 6a).
Two bands are seen, probably corresponding to the glyco-
sylated and nonglycosylated forms of the receptor. The
same bands appear (Figure 6b) in a Western blot using
affinity column–purified IgG from preeclamptic patient
serum. Identically handled serum from nonpreeclamptic
patients produced no bands. Confocal photomicrographs
(representative of four experiments) of VSMCs exposed to
affinity column–purified IgG from preeclamptic patient
serum and commercially available AT1 receptor antibody
are shown in Figure 7. A Cy3-labeled anti–human IgG anti-
body produced the red staining (Figure 7a; left). The same
cells were then exposed to commercially available AT1
receptor antibody (Figure 7a; center) with a Cy2-labeled sec-
ondary anti–human IgG antibody. Superimposition 
(Figure 7a; right) revealed that these antibodies colocalized.
The bottom panels of Figure 7 show the same procedure
with an IgG fraction from a pregnant, nonpreeclamptic
patient. Only staining from the commercially available AT1
receptor antibody is seen.
Finally, as shown in Figure 8, we tested to see if the
responses were mediated by protein kinase C (PKC). We
first observed an increase in beat number induced by
immunoglobulin from four patients (10 separate meas-
urements each) with preeclampsia, followed by PKC inhi-
bition with calphostin C. Calphostin C resulted in elimi-
nation of the increased beating response in 30 minutes.
Discussion
Our data suggest that immunoglobulin extracted from
the serum of preeclamptic patients contains an antibody
that binds to the AT1 receptor and has agonist activity.
The antibody subsides after the pregnancy is terminated.
Affinity-column purification and exposure to anti–
human IgG and IgM antibodies provide evidence that an
IgG autoantibody to the AT1 receptor is involved. Bind-
ing to the second loop of the AT1 receptor was implicat-
ed by the results of our second loop–containing peptide
experiment. Specificity was further supported by the
exposure to short, overlapping peptides of the second
extracellular loop. A lesser antibody response directed
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Figure 3
Increase in beat number induced by immunoglob-
ulin from patients with preeclampsia, complete
inhibition of the response by losartan (five
patients; open bars), and additional inhibition by
prazosin (five patients; hatched bars). The respons-
es indicate primary involvement of the AT1 recep-
tor and an additional response involving the a 1
adrenoceptor. The specificity of the AT1 response
is shown, in that the AT2 receptor blocker PD
123319 had no effect on any of the responses.
Figure 4
Increase in beat number induced by immunoglobulin from
patients with preeclampsia, the response after preexposure of the
immunoglobulin to a peptide consisting of the second extracel-
lular loop of the AT1 receptor, and additional inhibition by pra-
zosin. The response indicates inhibition of antibody directed
against the AT1 receptor by the peptide, thereby verifying the
specificity of the response. We included a control peptide con-
sisting of the second extracellular loop of the b 1-adrenergic recep-
tor. This peptide had no effect on the spontaneous beating rate.
against the a 1-adrenoceptor was detected in some of the
women. Pregnant women with preexisting hypertension
did not have antibody against the AT1 receptor; however,
some had antibody activity directed at the a 1-adrenergic
receptor, consistent with our earlier findings (8). We were
able to identify an AT1 receptor antibody, independent of
our bioassay, by means of Western blotting and confocal
microscopy in VSMCs. Finally, preliminary observations
with the PKC inhibitor calphostin C documented the
intracellular signaling and suggested that the postrecep-
tor signaling mechanism involves PKC. Our findings
raise the possibility that these antibodies may be of mech-
anistic importance in preeclampsia.
The renin–angiotensin system has been implicated in
preeclampsia. Gant et al. (2) identified hypersensitivity to
infused Ang II in preeclamptic patients, although the
angiotensin sensitivity test in preeclampsia is not invari-
ably positive (11). Calcium signaling is increased in
preeclamptic patients, with increased Ang II binding sites
on platelets (3). Sowers et al. (12) found elevated active tis-
sue renin concentrations and increased renin mRNA
expression in placentas from preeclamptic patients, com-
pared with placentas from women with normal pregnan-
cies. In their study, angiotensinogen tissue concentra-
tions and angiotensinogen mRNA expression were not
different between the two groups. Brar et al. (13) report-
ed somewhat similar findings. They observed increased
chorionic tissue active renin levels in patients with
preeclampsia, compared with controls. These results are
consistent with the reduced placental perfusion impli-
cated in the pathogenesis of preeclampsia (14).
Another line of evidence implicating the renin–
angiotensin system in preeclampsia stems from genetic
observations. A familial tendency toward preeclampsia
has been observed by several groups (15, 16). Ward et al.
(17) reported a significant association between
preeclampsia and the angiotensinogen variant T235 in
both Caucasian and Japanese subjects. Inoue et al. (18)
subsequently observed a mutation leading to the replace-
ment of leucine by phenylalanine at position 10 of
mature angiotensinogen (L10F), the site of renin 
cleavage, in a preeclamptic patient. This mutation sig-
nificantly alters the reactions of angiotensinogen with
both renin- and angiotensin-converting enzyme. As a
result, the catalytic efficiency is doubled. Inoue et al. sug-
gested that the L10F mutation might facilitate the devel-
opment of preeclampsia.
Autoantibodies directed at receptors are important in
myasthenia gravis (19) and Graves’ disease (20). In Graves’
disease, the antibodies exhibit agonist activity. A further
example that antibodies can activate receptors is the
demonstration that a monoclonal antibody was able to
activate the mutant insulin receptor Ser323Leu, which is
responsible for the Rabson-Mendenhall syndrome (21).
We have identified autoantibodies directed against the
b 1-adrenoceptor in patients with dilatative cardiomy-
opathy (9, 22) and against the a 1-adrenoceptor in
patients with malignant hypertension (23). Anti-AT1
autoantibodies have been described previously in patients
with malignant hypertension (24). The notion that such
autoantibodies are clinically important is supported by
the finding that patients with dilatative cardiomyopathy
and anti–b 1-adrenoceptor autoantibodies improved with
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Figure 5
Short, overlapping peptides corresponding to the second extracellular
loop of the AT1 receptor were prepared. These peptides were exposed to
affinity-purified antibody preparations. We tested the effect on the spon-
taneous beating rate of neonatal rat cardiomyocytes. The sequence
AFHYESQ abolished the response.
Figure 6
Western blot (representative of 4 experiments) of vascular smooth
muscle cell (VSMC) extract. Column (a) shows bands (arrows) pro-
duced by a commercial antibody directed against the AT1 receptor.
Column (b) shows bands produced by column-purified IgG from
preeclamptic patients. Column (c) shows identically handled col-
umn-purified IgG from nonpreeclamptic pregnant patients. Two
bands are probably the result of glycosylated and nonglycosylated
forms of the receptor.
immunoadsorption (25). Finally, in cardiomyopathy
patients treated with a left ventricular assist device,
improvement in cardiac function was associated with a
decrease in anti– b 1-adrenoceptor autoantibodies (26).
The fact that we were able to eliminate a chronotropic
effect of immunoglobulin from preeclamptic patients by
prior incubation with peptide segments contained in the
second extracellular loop of the AT1 receptor is a strong
argument in support of the notion that the autoanti-
bodies bind at these sites to the receptor in vivo. A three-
dimensional model of the AT1 receptor proposed by
Inoue et al. (27) suggests that Ang II binding may cause
each helix of the receptor to undergo appreciable rotation
to form bonding between transmembrane domain 7 and
transmembrane domain 2. Such bonding would con-
strain the receptor to adopt a unique conformation that
Inoue et al. termed the “agonist-bound” conformation.
This conformation then promotes G protein–coupled
signaling. We suggest that the autoantibodies are direct-
ed at extracellular loop 2 sites and activate the receptor
similar to its natural agonist, Ang II. The activation may
involve a cross-link between receptors that holds the
receptors in their activated conformation (28, 29). We
have unpublished preliminary evidence from experi-
ments using F(ab) fragments that such is the case for the
b 1-adrenoceptor autoantibodies, which we have
described previously in patients with dilatative car-
diomyopathy (24). However, alternative possibilities also
warrant consideration. Conceivably, interaction of the
autoantibody with the AT1 receptor alters the configura-
tion such that the receptor is more likely to be occupied
by Ang II. Ang II is undoubtedly present in the culture
media used for rat neonatal cardiomyocytes. Further-
more, evidence has been presented that neonatal car-
diomyocytes may produce their own Ang II, independent
of renin (30). Such an explanation would be more con-
sistent with the earlier findings of Gant et al. (2).
Preeclampsia is associated with abnormal placenta-
tion, reduced placental perfusion, endothelial cell dys-
function, and systemic vasospasm. An immune mecha-
nism has long been postulated (31). Increased prevalence
in multiple and molar pregnancies, and those associat-
ed with increased placental mass, suggests that tro-
phoblastic volume and fetal antigen load are correlated
with the syndrome. Kupferminc et al. (32) found that
tumor necrosis factor- a is increased in the plasma and
amniotic fluid of patients with preeclampsia, which is
consistent with abnormal immune activation. Hara et al.
(33) demonstrated the presence of interleukin-2 in decid-
ua cells of patients with preeclampsia, also consistent
with an enhanced immune response. Autoimmune
mechanisms have been postulated, including autoanti-
bodies directed against certain types of phospholipids or
trophoblastic constituents (34). As a result, corticos-
teroid therapy has been applied in severe preeclampsia,
with encouraging preliminary results (35).
We can only speculate on the mechanisms responsible
for the production of AT1 receptor antibodies in
preeclampsia. The AT1 receptor appears to be upregulat-
ed in preeclampsia. We and others have found that cir-
culating factors are directed against endothelial cells in
preeclampsia and cause their activation (36). We were
recently able to show that such a factor is responsible for
a marked increase in endothelial permeability and that
the mechanism is also PKC-mediated (37). Whether or
not this factor and the autoantibodies we describe here
are one and the same has yet to be proved; however, Ang
II is known to have a permeabilizing effect on endothe-
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Figure 7
Confocal photomicrograph (representative of four experiments) of VSMCs exposed to affinity column–purified IgG from preeclamptic patient serum
and commercially available AT1 receptor antibody. (a) A Cy3-labeled anti–human IgG antibody produced the red staining (left). The same cells were
simultaneously exposed to commercially available AT1 receptor antibody (center) with a Cy2-labeled secondary anti–human IgG antibody. Superim-
position (right) revealed that these antibodies colocalize (yellow). (b) The same procedure with IgG fraction from a pregnant nonpreeclamptic patient.
Only staining from the commercially available AT1 receptor antibody is seen.
a
b
lium (38). Maybe such preeclampsia-associated factors
are related to a disorderly receptor upregulation and sub-
sequent autoantibody production. AT1 receptor pro-
duction, in contrast to other components of the
renin–angiotensin system (11), has not been studied in
placental tissue to our knowledge. Conceivably, dimin-
ished placental perfusion could alter AT1 receptor
expression in an aberrant fashion, thereby permitting
autoantibody production.
A number of our observations remain unexplained. The
AT1 receptor antibody dissipates rapidly after delivery,
perhaps faster than can be explained by the half-life of
IgG, which ranges from about 7 to 21 days, depending on
the fraction. However, if complexes are formed, the dis-
appearance may be faster. The postdelivery samples we
have examined ranged between one and four weeks post-
partum. Genuine preeclampsia is said to be a disease of
first pregnancies, although the protective effect of multi-
parity is lost with change of partner (39). This observa-
tion raises the possibility of immune maladaptation. We
had six multiparous women in our study and did not
specifically inquire about or test for change of partner.
We are also not able to state for certain what the role of
activating AT1 receptor antibodies might be in terms of
explaining the clinical features of the preeclampsia syn-
drome, nor can we state how the antibodies are elicited.
In a single patient (not shown), we happened to have a
serum specimen at week 21 of pregnancy, while protein-
uria and elevated blood pressure first developed at week
24. At week 21, this patient had no AT1 receptor antibod-
ies. At week 24, antibodies were readily detectable and
peaked at week 26, at which time delivery was induced.
We made serial measurements after week 26 and observed
abatement of the antibodies over six weeks. This patient’s
course suggests that AT1 receptor antibodies first mani-
fest themselves shortly before the development of clinical
symptoms. However, the conditions leading to
preeclampsia may be established considerably earlier.
Zhou and colleagues (40) recently reported that
human cytotrophoblasts adopt a vascular phenotype as
they differentiate, which appears to be necessary for suc-
cessful endovascular invasion. This development occurs
in first half of pregnancy. They further observed that in
preeclampsia, human cytotrophoblasts fail to express
this vascular phenotype (41). Consequently, integrins,
cadherins, immunoglobulin superfamily members, and
perhaps other structures including surface receptors, are
not produced appropriately. Whether or not maldevel-
oped cytotrophoblastic endovascular invasion, with
compromised blood flow to the maternal–fetal interface,
leads to immunogenic structures is unknown. Local con-
centrations of growth factors, including vascular
endothelial growth factor (VEGF), are probably required
for the conversion of extravascular cells to endothelium
(42). Interestingly, Ang II interacts with VEGF and is able
to increase its angiogenic activity (43).
Our observations are preliminary. The autoanti-
body–receptor interaction must be studied in much
greater detail. Our precipitation experiments are a step
in this direction. The signaling pathway elicited by the
autoantibodies, including precise receptor conforma-
tion, must be elucidated in greater detail. Mutagenesis
studies will be required to realize that goal. The clinical
relevance of our findings will require clarification. Our
hope is to offer preeclamptic patients improved
options, particularly in terms of fetal growth and infant
survival. A strategy of autoantibody removal might be
a step in that direction.
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